Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q1 EPS of $0.55, $0.11 worse than the analyst estimate of $0.66. Revenue for the quarter came in at $438.7 million versus the consensus estimate of $473.37 million.

Vertex Pharmaceuticals, Inc. reaffirmed FY2012 guidance.

For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.

Earnings